Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Total Valuation
Bicycle Therapeutics has a market cap or net worth of $454.65M. The enterprise value is -$105.43M.
Market Cap$454.65M
Enterprise Value-$105.43M
Share Statistics
Bicycle Therapeutics has 49,929,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,929,950
Owned by Insiders22.68%
Owned by Institutions0.13%
Financial Efficiency
Bicycle Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -22.80%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-22.80%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee115.66K
Profits Per Employee-554.20K
Employee Count305
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicycle Therapeutics is ―. Bicycle Therapeutics’s PEG ratio is 0.11.
PE Ratio―
PS Ratio23.10
PB Ratio1.03
Price to Fair Value1.03
Price to FCF-4.91
Price to Operating Cash Flow-1.89
PEG Ratio0.11
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -2.91.
Revenue35.27M
Gross Profit-137.69M
Operating Income-209.87M
Pretax Income-173.80M
Net Income-169.03M
EBITDA-164.89M
Earnings Per Share (EPS)-2.91
Cash Flow
In the last 12 months, operating cash flow was -239.69M and capital expenditures -2.14M, giving a free cash flow of -241.87M billion.
Operating Cash Flow-239.69M
Free Cash Flow-241.87M
Free Cash Flow per Share-4.84
Dividends & Yields
Bicycle Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-70.95%
50-Day Moving Average7.58
200-Day Moving Average8.45
Relative Strength Index (RSI)39.08
Average Volume (3m)341.90K
Important Dates
Bicycle Therapeutics upcoming earnings date is Mar 3, 2026, Before Open (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Bicycle Therapeutics as a current ratio of 13.81, with Debt / Equity ratio of 0.16%
Current Ratio13.81
Quick Ratio13.81
Debt to Market Cap0.00
Net Debt to EBITDA5.28
Interest Coverage Ratio-121.31
Taxes
In the past 12 months, Bicycle Therapeutics has paid -4.76M in taxes.
Income Tax-4.76M
Effective Tax Rate0.03
Enterprise Valuation
Bicycle Therapeutics EV to EBITDA ratio is 0.33, with an EV/FCF ratio of 0.33.
EV to Sales-1.56
EV to EBITDA0.33
EV to Free Cash Flow0.33
EV to Operating Cash Flow0.33
Balance Sheet
Bicycle Therapeutics has $648.33M in cash and marketable securities with $981.00K in debt, giving a net cash position of $647.34M billion.
Cash & Marketable Securities$648.33M
Total Debt$981.00K
Net Cash$647.34M
Net Cash Per Share$12.97
Tangible Book Value Per Share$13.62
Margins
Gross margin is -592.00%, with operating margin of -594.96%, and net profit margin of -479.18%.
Gross Margin-592.00%
Operating Margin-594.96%
Pretax Margin-492.69%
Net Profit Margin-479.18%
EBITDA Margin-467.45%
EBIT Margin-487.78%
Analyst Forecast
The average price target for Bicycle Therapeutics is $22.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.29
Price Target Upside239.79% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-23.43%
EPS Growth Forecast-9.84%